Published in Nat Rev Gastroenterol Hepatol on July 01, 2009
Role of scavenger receptor class B type I in hepatitis C virus entry: kinetics and molecular determinants. J Virol (2010) 1.33
HCV causes chronic endoplasmic reticulum stress leading to adaptation and interference with the unfolded protein response. PLoS One (2011) 1.13
Hepatitis C virus inhibits AKT-tuberous sclerosis complex (TSC), the mechanistic target of rapamycin (MTOR) pathway, through endoplasmic reticulum stress to induce autophagy. Autophagy (2012) 1.05
Y-box-binding protein 1 interacts with hepatitis C virus NS3/4A and influences the equilibrium between viral RNA replication and infectious particle production. J Virol (2011) 0.91
Inhibition of enveloped virus infection of cultured cells by valproic acid. J Virol (2010) 0.88
Insights into cytokine-receptor interactions from cytokine engineering. Annu Rev Immunol (2014) 0.87
Host genetic basis for hepatitis C virus clearance: a role for blood collection centers. Curr Opin Hematol (2010) 0.87
Hepatitis C virus infection and risk of stroke: a systematic review and meta-analysis. PLoS One (2013) 0.86
A novel class of meso-tetrakis-porphyrin derivatives exhibits potent activities against hepatitis C virus genotype 1b replicons in vitro. Antimicrob Agents Chemother (2009) 0.84
Investigating a new generation of ribozymes in order to target HCV. PLoS One (2010) 0.84
N-substituted benzyl matrinic acid derivatives inhibit hepatitis C virus (HCV) replication through down-regulating host heat-stress cognate 70 (Hsc70) expression. PLoS One (2013) 0.84
Interferon alpha (IFNα)-induced TRIM22 interrupts HCV replication by ubiquitinating NS5A. Cell Mol Immunol (2015) 0.83
Attenuation of 40S ribosomal subunit abundance differentially affects host and HCV translation and suppresses HCV replication. PLoS Pathog (2012) 0.81
Host restriction factors for hepatitis C virus. World J Gastroenterol (2016) 0.78
Co-expression analysis of differentially expressed genes in hepatitis C virus-induced hepatocellular carcinoma. Mol Med Rep (2014) 0.76
Therapeutic development in targeting protein-protein interactions with synthetic topological mimetics. Curr Opin Pharmacol (2012) 0.75
The Amino Acid Substitution Q65H in the 2C Protein of Swine Vesicular Disease Virus Confers Resistance to Golgi Disrupting Drugs. Front Microbiol (2016) 0.75
Low-dose interferon-α treatment improves survival and inflammatory responses in a mouse model of fulminant acute respiratory distress syndrome. Inflammation (2013) 0.75
Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science (1999) 24.31
Complete replication of hepatitis C virus in cell culture. Science (2005) 18.59
Binding of hepatitis C virus to CD81. Science (1998) 12.40
Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med (2009) 12.07
Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med (2009) 10.21
Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature (2007) 9.52
Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis (2000) 6.54
Analysis of a successful immune response against hepatitis C virus. Immunity (1999) 6.31
Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology (2007) 6.12
Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J Virol (1992) 6.09
Unravelling hepatitis C virus replication from genome to function. Nature (2005) 5.25
Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Mol Cell (2005) 3.91
Structural biology of hepatitis C virus. Hepatology (2004) 3.40
Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients. Hepatology (2008) 3.14
Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin. Gastroenterology (2008) 2.73
The level of CD81 cell surface expression is a key determinant for productive entry of hepatitis C virus into host cells. J Virol (2006) 2.48
From structure to function: new insights into hepatitis C virus RNA replication. J Biol Chem (2005) 2.37
The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. Antimicrob Agents Chemother (2008) 2.22
Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication. Antiviral Res (2007) 2.14
Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. Gastroenterology (2008) 2.03
Inhibition of T-cell inflammatory cytokines, hepatocyte NF-kappaB signaling, and HCV infection by standardized Silymarin. Gastroenterology (2007) 1.85
A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C. Hepatology (2003) 1.73
NIM811, a cyclophilin inhibitor, exhibits potent in vitro activity against hepatitis C virus alone or in combination with alpha interferon. Antimicrob Agents Chemother (2006) 1.69
Viral heterogeneity of the hepatitis C virus. J Hepatol (1999) 1.62
Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies. J Hepatol (2007) 1.60
Self-assembly of nucleocapsid-like particles from recombinant hepatitis C virus core protein. J Virol (2001) 1.59
Activation of anti-hepatitis C virus responses via Toll-like receptor 7. Proc Natl Acad Sci U S A (2006) 1.59
Cell entry of hepatitis C virus. Virology (2006) 1.58
Short-term cytotoxic effects and long-term instability of RNAi delivered using lentiviral vectors. BMC Mol Biol (2004) 1.56
Human monoclonal antibodies that react with the E2 glycoprotein of hepatitis C virus and possess neutralizing activity. Hepatology (2005) 1.38
Cyanovirin-N inhibits hepatitis C virus entry by binding to envelope protein glycans. J Biol Chem (2006) 1.32
A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients. Liver Transpl (2005) 1.13
Raf-1 kinase associates with Hepatitis C virus NS5A and regulates viral replication. FEBS Lett (2005) 1.09
A phase I trial of an antisense inhibitor of hepatitis C virus (ISIS 14803), administered to chronic hepatitis C patients. J Hepatol (2005) 0.96
Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients with genotype 1 chronic hepatitis C. Hepatology (2008) 0.95
Effects of interferon, ribavirin, and iminosugar derivatives on cells persistently infected with noncytopathic bovine viral diarrhea virus. Antimicrob Agents Chemother (2004) 0.88
Clinical evaluation (Phase I) of a human monoclonal antibody against hepatitis C virus: safety and antiviral activity. J Hepatol (2006) 0.87
Hepatitis C and liver transplantation: enhancing outcomes and should patients be retransplanted. Clin Liver Dis (2008) 0.86
Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med (2011) 19.01
Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med (2013) 13.30
Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med (2009) 12.07
Telaprevir for previously treated chronic HCV infection. N Engl J Med (2010) 8.33
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med (2014) 8.13
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet (2012) 6.93
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology (2010) 6.14
Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med (2014) 3.40
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis (2013) 3.30
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med (2015) 3.16
Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients. Hepatology (2008) 3.14
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol (2008) 2.97
Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C. Hepatology (2008) 2.81
Significant pulmonary toxicity associated with interferon and ribavirin therapy for hepatitis C. Am J Gastroenterol (2002) 2.55
Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C. Brain Behav Immun (2005) 2.52
Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C. Blood (2005) 2.50
Clonal B cells in patients with hepatitis C virus-associated mixed cryoglobulinemia contain an expanded anergic CD21low B-cell subset. Blood (2011) 2.49
Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol (2007) 2.16
Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus. Hepatology (2014) 2.04
Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology (2012) 1.95
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol (2006) 1.92
Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus. Hepatology (2007) 1.73
Clonal expansion of immunoglobulin M+CD27+ B cells in HCV-associated mixed cryoglobulinemia. Blood (2007) 1.72
Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials. Clin Infect Dis (2013) 1.62
Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients. J Hepatol (2011) 1.59
Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. J Clin Psychiatry (2005) 1.58
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin Gastroenterol Hepatol (2004) 1.47
HIV/hepatitis C virus-coinfected patients with normal alanine aminotransferase levels. J Acquir Immune Defic Syndr (2006) 1.44
Peripheral CXCR3-associated chemokines as biomarkers of fibrosis in chronic hepatitis C virus infection. J Infect Dis (2009) 1.36
Presence of functional dendritic cells in patients chronically infected with hepatitis C virus. Blood (2003) 1.33
Normal functional capacity in circulating myeloid and plasmacytoid dendritic cells in patients with chronic hepatitis C. J Infect Dis (2005) 1.31
Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis. Clin Infect Dis (2012) 1.20
Accumulation of B lymphocytes with a naive, resting phenotype in a subset of hepatitis C patients. J Immunol (2003) 1.19
Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials. PLoS One (2012) 1.19
Recent successes and noteworthy future prospects in the treatment of chronic hepatitis C. Clin Infect Dis (2012) 1.14
Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens. Hepatology (2014) 1.10
Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection. Gastroenterology (2012) 1.09
Emerging therapies for the treatment of hepatitis C. EMBO Mol Med (2014) 1.09
Daclatasvir plus sofosbuvir for HCV infection. N Engl J Med (2014) 1.04
Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial. Hepatology (2013) 1.03
Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety. Am J Gastroenterol (2003) 1.02
Managing patients with hepatitis‑B-related or hepatitis‑C-related decompensated cirrhosis. Nat Rev Gastroenterol Hepatol (2011) 1.02
Quality-of-life tradeoffs for hepatitis C treatment: do patients and providers agree? Med Decis Making (2008) 1.02
Telaprevir-based treatment effects on hepatitis C virus in liver and blood. Hepatology (2014) 0.99
Transjugular intrahepatic portosystemic shunt for refractory ascites: an analysis of the literature on efficacy, morbidity, and mortality. Am J Gastroenterol (2003) 0.95
Lessons from HIV therapy applied to viral hepatitis therapy: summary of a workshop. Am J Gastroenterol (2010) 0.95
Intrahepatic CD4+ cell depletion in hepatitis C virus/HIV-coinfected patients. J Acquir Immune Defic Syndr (2004) 0.95
The first wave: HCV NS3 protease inhibitors telaprevir and boceprevir. Antivir Ther (2012) 0.94
Customizing the management of chronic hepatitis B virus infection. Semin Liver Dis (2007) 0.92
How to use statins in patients with chronic liver disease. Cleve Clin J Med (2004) 0.89
Resistance-associated amino acid variants associated with boceprevir plus pegylated interferon-α2b and ribavirin in patients with chronic hepatitis C in the SPRINT-1 trial. Antivir Ther (2013) 0.88
Impact of Hispanic or Asian ethnicity on the treatment outcomes of chronic hepatitis C: results from the WIN-R trial. J Clin Gastroenterol (2011) 0.86
Prognostic significance of hepatitis C virus RNA detection by transcription-mediated amplification with negative polymerase chain reaction during therapy with peginterferon alpha and ribavirin. Dig Dis Sci (2007) 0.84
Advances in the treatment of hepatitis C virus infection. Gastroenterol Hepatol (N Y) (2012) 0.83
Seizures during pegylated interferon and ribavirin therapy for chronic Hepatitis C: observations from the WIN-R trial. J Clin Gastroenterol (2011) 0.83
Treating chronic hepatitis B infection in patients who are pregnant or are undergoing immunosuppressive chemotherapy. Semin Liver Dis (2007) 0.82
Combination therapy for chronic hepatitis B: ready for prime time? J Hepatol (2008) 0.82
The role of the woodchuck model in the treatment of hepatitis B virus infection. Clin Liver Dis (2007) 0.82
IL28B polymorphism, pretreatment CXCL10, and HCV RNA levels predict treatment response in racially diverse HIV/HCV coinfected and HCV monoinfected patients. J Acquir Immune Defic Syndr (2013) 0.81
Resistance-associated variants in chronic hepatitis C patients treated with protease inhibitors. Curr Gastroenterol Rep (2012) 0.81
Persistence of hepatitis C virus during and after otherwise clinically successful treatment of chronic hepatitis C with standard pegylated interferon α-2b and ribavirin therapy. PLoS One (2013) 0.81
Emerging therapeutic targets for hepatitis C virus infection. Clin Gastroenterol Hepatol (2013) 0.80
Futility rules for telaprevir combination treatment for patients with hepatitis C virus infection. Clin Gastroenterol Hepatol (2012) 0.80
Cardiovascular diseases and the liver. Clin Liver Dis (2011) 0.80
Safety, pharmacokinetics and pharmacodynamics of the oral toll-like receptor 7 agonist GS-9620 in treatment-naive patients with chronic hepatitis C. Antivir Ther (2014) 0.79
Cost-effectiveness of truncated therapy for hepatitis C based on rapid virologic response. Value Health (2012) 0.79
VX-222, a non-nucleoside NS5B polymerase inhibitor, in telaprevir-based regimens for genotype 1 hepatitis C virus infection. Eur J Gastroenterol Hepatol (2014) 0.78
Hepatocyte proliferation in chronic hepatitis C: correlation with degree of liver disease and serum alpha-fetoprotein. Liver Int (2004) 0.78
Telaprevir: hope on the horizon, getting closer. Clin Liver Dis (2009) 0.78
Boceprevir plus peginterferon α-2b/ribavirin in chronic hepatitis C genotype 1: impact of baseline viral load on sustained virologic response. J Clin Gastroenterol (2014) 0.77
Tenofovir disoproxil fumarate in Asian or Pacific Islander chronic hepatitis B patients with high viral load (≥ 9 log10 copies/ml). Liver Int (2014) 0.77
Randomized trial comparing dose reduction and growth factor supplementation for management of hematological side effects in HIV/hepatitis C virus patients receiving pegylated-interferon and ribavirin. J Acquir Immune Defic Syndr (2011) 0.77
Entering the new era of therapy for HBV and HCV infections. J Fam Pract (2010) 0.77
Advancing patient care: integrating new data. Am J Gastroenterol (2006) 0.76
Liver disease. The influence of SOCS3 expression on the treatment response of HCV-related chronic hepatitis patients. Rev Gastroenterol Disord (2008) 0.75
WIN-R revisited: Response to editorial. Hepatology (2008) 0.75
Chronic hepatitis C genotype 2 and 3: are we ready for personalized medicine? J Hepatol (2011) 0.75
Screening and diagnosis of cholangiocarcinoma in patients with primary sclerosing cholangitis. Rev Gastroenterol Disord (2009) 0.75
Slowing the progression of chronic hepatitis B. Early antiviral therapy can help minimize complications. Postgrad Med (2003) 0.75
Halting the natural history of hepatitis B viral infection: a paradigm shift. Semin Liver Dis (2007) 0.75
Treatment of relapsers after combination therapy for chronic hepatitis C. Infect Dis Clin North Am (2006) 0.75
Treatment of relapsers after combination therapy for chronic hepatitis C. Gastroenterol Clin North Am (2004) 0.75
Optimal treatment with telaprevir for chronic HCV infection. Liver Int (2013) 0.75
Clinical course of chronic hepatitis C in patients with very high serum alpha-fetoprotein levels and normal hepatic imaging. Am J Gastroenterol (2005) 0.75
The role of hematopoietic growth factors in special populations with chronic hepatitis C: patients with HIV coinfection, end-stage renal disease, or liver transplantation. Cleve Clin J Med (2004) 0.75
Fenofibrate-induced cirrhosis. Dig Dis Sci (2005) 0.75
Role of the nurse practitioner in the management of patients with chronic hepatitis C. J Am Acad Nurse Pract (2011) 0.75
Telaprevir for chronic hepatitis C virus infection. Clin Liver Dis (2013) 0.75